NORDIC BIOSCIENCE CLINICAL DEVELOPMENT VII A/S: Financial statements 2014
CVR: 33249098
Source: annual report 2014, Danish Business Authority
01/01/2014 – 31/12/2014
NORDIC BIOSCIENCE CLINICAL DEVELOPMENT VII A/S (CVR 33249098) has filed annual accounts for 2014. In 2014, the company reported a gross profit of DKK 41,981,534 and a net result of DKK 32,351,010 compared with DKK 3,170,924 the year before. That is an increase of 906.1% compared with the year before. Equity in the 2014 report amounted to DKK 38,595,382. The solvency ratio was 58.5%.
- Gross Profit
- DKK 41,981,534
- Profit/Loss
- DKK 32,351,010
- Equity
- DKK 38,595,382
- Total Assets
- DKK 65,983,069
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2014 | - | 42 mio. | 32.4 mio. | 38.6 mio. | - |
| 2013 | - | 4.2 mio. | 3.2 mio. | 6.2 mio. | - |
| 2012 | - | - | - | 500 t. | - |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2014
NORDIC BIOSCIENCE CLINICAL DEVELOPMENT VII A/S has published its annual report for 2013. Gross profit came to DKK 4,172,733, and the net result was DKK 3,170,924.
As of January 1, 2014, Jeppe Ragnar Andersen is registered as adm. dir. of NORDIC BIOSCIENCE CLINICAL DEVELOPMENT VII A/S.
As of January 1, 2014, Bente Juel Christiansen has stepped down as director of NORDIC BIOSCIENCE CLINICAL DEVELOPMENT VII A/S.
About NORDIC BIOSCIENCE CLINICAL DEVELOPMENT VII A/S
NORDIC BIOSCIENCE CLINICAL DEVELOPMENT VII A/S was a Danish company of the type Aktieselskab based in Herlev, founded in 2010. The company has been dissolved on 25 May 2021. The company was registered under the industry Forskning og eksperimentel udvikling indenfor bioteknologi. According to the 2019 annual report, the company had an average of 0 employees. In 2019, the company reported a gross profit of DKK 248,136 and a net result of DKK 164,772 compared with DKK 954,488 the year before. Equity in the 2019 report amounted to DKK 725,098.